Effectiveness of Introducing Ultra-High B-Value Diffusion-Weighted Imaging as a Modified Abbreviated Protocol for Breast Cancer Detection

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06970288

Enrollment

Registered

2025-05-14

Start date

2025-05-10

Completion date

2026-12-30

Last updated

2025-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Carcinoma

Brief summary

The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 50 Years

Healthy volunteers

Inclusion criteria

* • Women with suspicious breast mass (BIRADS 4a) * High risk women (Positive family history) * Women with suspicious axillary lymph nodes by Ultrasound * Women with dense breasts coming for MRI imaging.

Exclusion criteria

* • Contraindications to MRI * Pacemaker, cochlear implant, claustrophobia, ocular implants * Contraindications to contrast administration: * Elevated kidney functions * Women who haven't undergone reliable Mammogram & Ultrasound * Women with prior treatment or intervention (e.g. biopsy) * Patients' refusal.

Design outcomes

Primary

Measure	Time frame
To evaluate the capability of detecting suspicious breast lesions using non-contrast enhanced MRI protocol featuring ultra-high B-value	20 months

Countries

Egypt

Contacts

Primary ContactAhmed Mohamed Aly

ahmedaly@med.asu.edu.eg+201273726233

Outcome results